{"meshTagsMajor":["Quinolines","Molecular Targeted Therapy","Angiogenesis Inhibitors","Biomarkers, Tumor","Phenylurea Compounds"],"meshTags":["Proto-Oncogene Proteins B-raf","PTEN Phosphohydrolase","Quinolines","Neoplasms","Skin Neoplasms","Translational Medical Research","Melanoma","Receptors, Vascular Endothelial Growth Factor","Animals","Disease Models, Animal","Molecular Targeted Therapy","Humans","Mutation","Drug Evaluation, Preclinical","Angiogenesis Inhibitors","Precision Medicine","Biomarkers, Tumor","Phenylurea Compounds"],"meshMinor":["Proto-Oncogene Proteins B-raf","PTEN Phosphohydrolase","Neoplasms","Skin Neoplasms","Translational Medical Research","Melanoma","Receptors, Vascular Endothelial Growth Factor","Animals","Disease Models, Animal","Humans","Mutation","Drug Evaluation, Preclinical","Precision Medicine"],"genes":["anti-angiogenic inhibitor Lenvatinib mesylate","E7080"],"organisms":["9606"],"publicationTypes":["Journal Article","Review"],"title":"[Preclinical biomarker research and patient stratification of molecular target agents: the anti-angiogenic inhibitor Lenvatinib mesylate (E7080)].","pubmedId":"24107519"}